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Abstract 
Small-cell lung cancer (SCLC) is highly sensitive to platinum-based chemotherapy. How-
ever, its indication in patients with a poor performance status (PS) at initial diagnosis is 
controversial. We retrospectively reviewed all clinical courses of pathologically diagnosed 
SCLC patients with poor PS, Eastern Cooperative Oncology Group PS 3 and 4. Among 18 
patients, 12 were treated with chemotherapy and 6 with supportive care alone. During the 
chemotherapy courses, PS improved in 7 (58.3%, including the PS 4 cases), remained sta-
ble in 2 (16.7%), and deteriorated in 3 (25%) patients. Moreover, 5 patients showed partial 
responses to chemotherapy (response rate of 41.7%). Grade 3–4 neutropenia developed 
in 10 (83.3%) patients and grade 3 febrile neutropenia occurred in 5 (41.7%) patients, but 
no grade 4 non-hematological toxicity was noted. Mortality associated with lung toxicity 
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(grade 5) due to treatment occurred in a 77-year-old-male patient with PS 3. No substan-
tial difference in survival was observed between patients with PS 3 and 4, even when in-
cluding those treated with supportive care alone. Treatment had a positive effect on sur-
vival: after chemotherapy, the 6-month survival rate of PS 3 and 4 patients was 66.7%. In 
contrast, all patients treated with supportive care alone died within 5 months. These find-
ings suggest that chemotherapy is indicated in selected SCLC patients not only with PS 3, 
but also with PS 4. © 2019 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Small-cell lung cancer (SCLC) accounts for about 13% of all lung cancers in Japan, alt-
hough its incidence has been gradually declining [1]. As it spreads rapidly to other body parts, 
more than 60% of newly diagnosed SCLC patients present extensive disease [2]. Moreover, 
the prognosis of these patients is very poor with a median survival of only 1–2 months on 
supportive care alone [3]. 
Ever since a significant survival benefit with cyclophosphamide monotherapy was shown 
in a randomized trial in 1960s [4], chemotherapy has been universally used to treat SCLC pa-
tients in a good general condition. Although SCLC is highly sensitive to platinum-based chem-
otherapy, its indication in patients with a poor performance status (PS, Eastern Cooperative 
Oncology Group [ECOG] PS 3 and 4) at initial diagnosis is still controversial, due to high treat-
ment-related mortality risk of such patients [5, 6].  
There has been only one randomized trial that evaluated platinum-based chemotherapy 
for poor-risk SCLC treatment in PS 3 patients <70 years of age) and PS 0–2 (ECOG, good PS) 
patients ≥70 years of age. In this study, a subgroup analysis showed a median overall survival 
of 7.1 months in the patients with PS 3 treated with carboplatin and etoposide, and of 6.9 
months in those treated with cisplatin and etoposide, without death occurrence due to toxicity 
of either treatment [7]. Regarding the results of a retrospective case series, the objective re-
sponse rate to combined platinum and etoposide chemotherapy was 67% and the median 
overall survival was 2.1 months in patients with PS 3, which corresponded to 20% and 7 days, 
respectively, in those with PS 4. Additionally, 20% of PS 3 patients and 60% of PS 4 patients 
died shortly after the first chemotherapy cycle [8]. Moreover, in another case series study of 
the effect of chemotherapy on poor-risk SCLC, the objective response rate and median overall 
survival were 75% and 8.4 months, respectively, in patients with PS 3, in contrast to 40% and 
4.8 months, respectively, in those with PS 4 [9]. In addition, one patient with each PS died due 
to chemotherapy-related toxicity [9]. All these studies show discrepant results, which may be 
attributable to differences in patients’ characteristics between clinical trials and clinical prac-
tice. Nonetheless, this issue should be addressed carefully to achieve a standard clinical treat-
ment for such debilitated patients. Furthermore, only patients who received chemotherapy 
were included in these studies, however, best supportive care in clinical settings is also an 
alternative treatment to consider. 
Therefore, the main objective of our retrospective case series study was to evaluate the 
clinical courses of extensive SCLC patients with poor PS at initial diagnosis in order to identify 
optimal treatment options.  
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Patients and Methods 
We conducted a retrospective review of the clinical data of 18 pathologically diagnosed 
SCLC patients with poor PS, ECOG PS 3 and 4, treated at University of Tsukuba Hospital be-
tween April 2000 and May 2017.  
The data collected from medical records of our hospital were as follows: medical history, 
physical examination on admission, pathological diagnosis, laboratorial and radiological find-
ings, treatment regimen and respective adverse events/toxicity, ECOG PS grade variation (be-
fore and during chemotherapy), and patient’s clinical course. 
Furthermore, tumor responses to treatment were evaluated according to World Health 
Organization response criteria [10]. Treatment toxicities were evaluated according to Com-
mon Terminology Criteria for Adverse Events version 4.0. 
The overall survival was determined from the pathological diagnosis to patient’s death or 
last follow-up.  
Statistical analyses were performed with Statistical Package for Social Sciences Soft Ware 
version 25.0. Survival curves were estimated by the Kaplan-Meier method and compared by 
the log rank test.  
Results 
Patient Characteristics 
Among 142 patients diagnosed with SCLC by cytological or histological examination at 
out hospital, 12 had a PS 3 and 6 had a PS 4 at initial diagnosis. Table 1 summarizes the char-
acteristics of the patients considered for study. Overall, 14 males and 4 females were included, 
with a median age of 73 years. There were no large differences in age, gender, or tumor-re-
lated factors between patients with PS 3 and 4.  
Treatment 
Twelve patients, with both PS3 and 4, were treated with chemotherapy and 6 patients 
with best supportive care alone (Table 1). Chemotherapy was not administered in 2 patients 
with PS3 due to severe comorbidities and mental disease. The chemotherapeutic regimen was 
a combination of carboplatin and etoposide in 11 out of those 12 patients. Of these, 7 patients 
received the standard dose, carboplatin area under the curve (AUC) of 5 intravenously on day 
1 and etoposide 80–100 mg/m2 intravenously on days 1–3. In the remaining 4 patients, the 
doses of carboplatin and etoposide were reduced to AUC of 4 and 50–80 mg/m2, respectively. 
One patient was only treated with carboplatin AUC of 5 because the serum total bilirubin level 
was high (>5 mg/dL) and he presented hepatic metastases. The number of chemotherapy cy-
cles in the first-line chemotherapy ranged from 1 to 4 (50% of patients underwent 4 cycles; 
8.3%, 3; 8.3%, 2; 33.3%, 1). Second-line chemotherapy was administered to 5 patients.  
Whole brain radiation therapy was administered to 4 patients before chemotherapy and 
stereotactic radiotherapy for brain metastasis was administered to 1 patient. Additionally, 1 
patient underwent palliative thoracic radiotherapy at a dose of 30.6 Gy in 17 fractions.  
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Improvement of PS 
During chemotherapy, PS improved in 7 (58.3%) patients. This was observed in the 2  
patients with PS 4 (Table 1): 1 patient shifted to PS 2, and the other shifted to PS 1. In addi-
tion, PS remained unchanged in 2 (16.7%) patients, while it deteriorated in 3 (25%) patients 
(Fig. 1). 
Toxicity 
Grade 3–4 neutropenia developed in 10 (83%), and grade 3 febrile neutropenia in 5 
(42%) patients (Table 2). Treatment-related mortality associated with lung toxicity occurred 
in a 77-year-old male patient with PS 3. There were 3 early deaths within 4 weeks of treat-
ment; these patients were all treated with supportive care alone and died of lung cancer pro-
gression.  
Objective Response and Overall Survival 
Considering all 18 patients studied, the median overall survival and 6-month survival rate 
were 4.9 months and 47.9%, respectively. The overall survival of the patients with PS 4 was 
comparable to that of the patients with PS 3; the 6-month survival rate was 50% in both 
groups (log rank p = 0.31, Fig. 2). 
During chemotherapy, there were 5 partial responses (objective response rate of 41.7%), 
3 stable disease (25%), and 4 progressive disease (33.3%). Treatment significantly affected 
survival: the 6-month survival rate was 66.7% in those patients treated with chemotherapy, 
while all patients treated with supportive care alone died within the first 5 months (logrank  
p = 0.037, Fig. 3). 
Discussion 
It is difficult to select the best treatment option in SCLC patients with a poor PS because 
occasionally chemotherapy is too toxic to be administered to patients in such a poor general 
condition. In this study, one patient (aged 77 years) with PS 3 died of chemotherapy, which 
might be explained by the patient’s advanced age. Although toxicity was tolerable in the other 
patients studied (Table 2), it was reported that both poor PS and advanced age are significant 
factors associated with toxic death in patients with SCLC [5], as well as in those with breast 
and non-small-cell lung cancers [6]. 
On the contrary, patient’s general condition may actually take a turn for the better when 
active systemic chemotherapy is administered. Indeed, in this study, a considerable improve-
ment in PS after chemotherapy was observed in 7 of 12 (58%) patients. This is comparable to 
the response rate to carboplatin and etoposide in elderly patients with extensive SCLC re-
ported in a phase III trial [7]. Thus, it is reasonable to expect a PS improvement with systemic 
chemotherapy in SCLC having a poor PS.  
The current Japanese lung cancer guidelines provide the treatment options for SCLC pa-
tients with PS 3 and 4 separately [11]. According to those, platinum doublets are recom-
mended for patients with PS 3. However, this is based on only one phase III trial, which in-
cluded 18 patients with PS 3. In addition, this study excluded elderly patients >70 years of age, 
but currently this group corresponds to about half of the patients with a poor PS. Regarding 
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patients with PS 4, the guidelines do not recommend chemotherapy because there are no 
available supportive data. However, we report on two patients with PS 4 in whom carboplatin 
and etoposide combined chemotherapy was so effective that their PS improved significantly. 
Accordingly, they were able to receive a total of four cycles of chemotherapy without life-
threatening toxicity. Although our number of patients was limited, overall survival did not dif-
fer between patients with PS 3 and 4, even when the patients treated with supportive care 
alone were included in the analysis. Importantly, the American guidelines for the treatment of 
SCLC do not consider patients with PS 3 and 4 separately, and recommend chemotherapy for 
all if the poor PS is a result of the SCLC itself [12–14]. Therefore, our findings strongly suggest 
that chemotherapy is indicated in selected SCLC patients with both PS 3 and 4 if the poor PS 
is mostly due SCLC rather than by comorbidities, as an improvement of PS due to treatment is 
expected. 
In conclusion, the poor PS was improved significantly in about 58% of patients with ag-
gressive systemic chemotherapy, strongly suggesting that chemotherapy is indicated in se-
lected SCLC patients with both PS 3 and 4. 
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Fig. 1. Performance status (PS) variation during chemotherapy courses. As a result of treatment, PS im-
proved in 7 (58.3%), remained stable in 2 (16.7%), and deteriorated in 3 (25%) patients. Solid lines: pa-
tients who received standard chemotherapy; Dashed lines: patients who received chemotherapy at low 
doses; PS is categorized as 1–4.  
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Fig. 2. Patients’ overall survival according to performance status (PS). Solid line: patients with PS 3 (n = 
12); Dotted line: patients with PS 4 (n = 6). 
 
 
 
Fig. 3. Patients’ overall survival according to treatment type. Solid line: patients treated with chemother-
apy (n = 12); Dotted line: patients treated with supportive care alone (n = 6). 
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Table 1. Patients’ characteristics 
    
    
 PS 3 (n = 12) PS 4 (n = 6) Total (n = 18)  
       
       
Age, years       
Median (range) 74.5 (51–85) 070.5 (64–77) 073 (51–85) 
Gender, n (%)       
Male 00.8 (66.7)  000.6 (100)  014 (77.8) 
Female 00.4 (33.3)  000.0  004 (22.2) 
Superior vena cava syndrome, n (%)     
Yes 00.2 (16.7) 000.1 (16.7) 003 (16.7) 
No 0.10 (83.3) 000.5 (83.3) 015 (83.3) 
Brain metastases, n (%)       
Yes 00.6 (50)  000.3 (50)  009 (50) 
No 00.6 (50)  000.2 (33.3)  008 (44.4) 
Unknown 00.0 000.1 (16.7)  001 (5.6) 
Serum LDH, IU/L       
Median (range) .263 (170–877) 597.5 (205–5,739) 352 (170–5,739) 
Treatment, n (%)       
Chemotherapy 0.10 (83.3)  000.2 (33.3)  012 (66.7) 
Supportive care alone 00.2 (16.7)  000.4 (66.7)  006 (33.3) 
       
       
 
 
Table 2. Toxicity of first-line chemotherapy (Grade 3–5) 
     
     
 Toxicity, n (%) 
   grade 3 grade 4  grade 5 grade 3–5 (total)  
     
     
Neutropenia 4 (33.3) 6 (50)  0 10 (83.3)  
Anemia 4 (33.3) 1 (8.3)  0 05 (41.7)  
Thrombocytopenia 5 (41.7) 1 (8.3)  0 06 (50)  
Febrile neutropenia 4 (33.3) 0 0 04 (33.3)  
Dyspnea 0 0 1 (8.3) 01 (8.3) 
     
     
n, number of patients. 
 
 
 
 
 
